Stay updated on MAPP2 MDMA Therapy Clinical Trial
Sign up to get notified when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.

Latest updates to the MAPP2 MDMA Therapy Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the usual study content and documents with a generic error screen.SummaryDifference19%

- Check16 days agoChange DetectedIsrael locations list updated: Tel Litwinsky, Israel added as a participating site and Qiryat Krinitzi, Israel removed.SummaryDifference0.1%

- Check23 days agoChange DetectedThe addition of Qiryat Krinitzi, Israel as a study site expands the list of locations for participant enrollment. Tel Litwinsky, Israel has been removed from the list of participating sites.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, indicating a small page version update. No changes to the study content or data are indicated.SummaryDifference0.1%

- Check51 days agoChange DetectedThe study documents show a new revision (v3.6.5) replacing the previous v3.6.4, indicating an updated version of the study plan or related materials.SummaryDifference0.0%

- Check66 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, signaling a small internal update to the page’s documentation and versioning.SummaryDifference0.0%

Stay in the know with updates to MAPP2 MDMA Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.